HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project

In 2014, UNAIDS launched renewed global targets for HIV control to achieve by 2025, known as “the three 95”: 95% of people living with HIV (PWH) diagnosed, of which 95% are receiving treatment, of which 95% are on sustained virological suppression. In Italy, new HIV diagnoses have been steadily decreasing since 2012. However, in 2020, 41% of new diagnoses presented with less than 200 CD4+ cells/µL and 60% with less than 350 CD4+ cells/µL. Implementing testing and early treatment is a key strategy to prevent AIDS, late presentation, and HIV transmission. We selected non-Infectious Diseases Units based on the European project HIDES and engaged colleagues in a condition-guided HIV screening strategy. We enrolled 300 patients, of which 202 were males (67.3%) and 98 were females (32.7%). Most of the screening was performed in Infectious Diseases (ID) and Hematologic wards. In total, we diagnosed eleven new HIV infections with a hospital prevalence in the study population of 3.7%. Five (45.4%) had a CD4 count <100/mm3, one (9.1%) <200/mm3, and one (9.1%) <300/mm3. Regarding risk factors, 81.8% declared having had unprotected sexual intercourse and 54.5% were heterosexual. All patients promptly started a combination antiretroviral regimen and 10 (90.9%) obtained an undetectable HIV-RNA status. Eight of the eleven (72.7%) patients are currently on follow-up in our outpatient clinic. A proactive indicator disease-guided screening can help avoid missed opportunities to diagnose HIV infection in a hospital setting. Implementing this kind of intervention could favor early diagnosis and access to treatment.

[1]  T. van der Poll,et al.  Improving indicator-condition guided testing for HIV in the hospital setting (PROTEST 2·0): A multicenter, interrupted time-series analysis , 2022, The Lancet regional health. Europe.

[2]  M. C. Meloni,et al.  How Little Do We Know about HIV and STIs Prevention? Results from a Web-Based Survey among the General Population , 2022, Healthcare.

[3]  Moira Walsh,et al.  “It is not an acceptable disease”: A qualitative study of HIV-related stigma and discrimination and impacts on health and wellbeing for people from ethnically diverse backgrounds in Australia , 2021, BMC Public Health.

[4]  A. Antinori,et al.  Time spent with viral load≤200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era. , 2021, AIDS.

[5]  A. Amato-Gauci,et al.  HIV testing strategies employed in health care settings in the European Union/European Economic Area (EU/EEA): evidence from a systematic review , 2019, HIV medicine.

[6]  G. d’Ettorre,et al.  Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: Results from a multicenter cohort study. , 2019, Antiviral research.

[7]  Hansjakob Furrer,et al.  Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study , 2019, The Lancet.

[8]  M. Boffito,et al.  Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps , 2019, HIV medicine.

[9]  Felipe García,et al.  Indicator condition-guided HIV testing with an electronic prompt in primary healthcare: a before and after evaluation of an intervention , 2019, Sexually Transmitted Infections.

[10]  P. Narciso,et al.  Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial , 2018, The Journal of antimicrobial chemotherapy.

[11]  N. Ford,et al.  Benefits and risks of rapid initiation of antiretroviral therapy , 2017, AIDS.

[12]  Pietro Vernazza,et al.  Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. , 2016, JAMA.

[13]  A. Grzeszczuk,et al.  Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study , 2015, PloS one.

[14]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[15]  D. Cooper,et al.  The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods , 2014, BMC Public Health.

[16]  C. Murrill,et al.  Global epidemiology of HIV. , 2014, Infectious disease clinics of North America.

[17]  Stefan Esser,et al.  Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) , 2013, PloS one.

[18]  C. Watkins-Hayes Ending the AIDS epidemic , 2012 .

[19]  Myron S. Cohen,et al.  HIV treatment as prevention and HPTN 052. , 2012, Current opinion in HIV and AIDS.

[20]  Christine A. Lee,et al.  The natural history of HIV infection. , 1989, AIDS care.